Gut Healing Protocol

The Gut Healing Protocol combines BPC-157 administered orally with Larazotide (AT-1001) to address intestinal permeability and mucosal damage from the luminal side. BPC-157, originally isolated from human gastric juice, has a natural affinity for gastrointestinal tissue. When taken orally, it acts locally on the GI mucosa to promote healing of ulcerations, reduce inflammation, and restore tight junction integrity. Studies in animal models demonstrate its efficacy against NSAID-induced gut damage, inflammatory bowel conditions, and anastomosis healing. Larazotide acetate is an 8-amino-acid synthetic peptide that acts as a tight junction regulator. It works by inhibiting zonulin-mediated opening of intestinal tight junctions — the primary mechanism behind increased intestinal permeability ("leaky gut"). Larazotide completed Phase 3 clinical trials for celiac disease, where it demonstrated significant reduction in symptoms triggered by gluten exposure, confirming its mechanism of action in human subjects. Though not yet FDA-approved, it represents one of the most clinically validated peptides for gut barrier function. The combination works synergistically because BPC-157 addresses the underlying mucosal damage and inflammation driving gut dysfunction, while Larazotide provides immediate functional restoration of the tight junction barrier. BPC-157 heals the tissue; Larazotide prevents further permeability while healing occurs. This dual-mechanism approach addresses both the cause and consequence of intestinal hyperpermeability, making it suitable for individuals with IBS, post-infectious gut dysfunction, NSAID-induced enteropathy, or chronic intestinal inflammation. The oral route for both compounds makes this an accessible protocol requiring no injections.